Table 3 Univariable and multivariable analysis of the treosulfan cohort.

From: Treosulfan-induced myalgia in pediatric hematopoietic stem cell transplantation identified by an electronic health record text mining tool

Variable

OR 95% CI

p-value

Adjusted OR 95% CI*

p-value

Underlying disease

Hemoglobinopathy

9.16 (3.58–26.97)

 < 0.001

7.16 (2.09–30.03)

0.003

Age

 > 3 years of age

10.3 (3.34–45.50)

 < 0.001

8.98 (2.04–64.54)

0.01

Conditioning regimen

Treo-Flu

0.28 (0.09–0.74)

0.02

0.64 (0.14–2.92)

0.57

Treo-Other

1.71 (0.07–44.50)

0.71

1.73 (0.05–71.17)

0.75

Treosulfan exposure (AUC0-∞) (for every 500 mg*hr/L increase in AUC0-∞)

0.34 (0.17–0.64)

0.002

0.61 (0.26–1.33)

0.23

  1. Treo treosulfan, Flu fludarabine, AUC Area under the concentration curve.
  2. Adjusted for underlying disease, age, conditioning regimen and treosulfan exposure.
Back to article page